- Home
- ONVO vs LIPO Comparison
ONVO vs LIPO Comparison
Compare ONVO & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- LIPO
- Stock Information
- Founded
- ONVO 2007
- LIPO 2005
- Country
- ONVO United States
- LIPO United States
- Employees
- ONVO N/A
- LIPO N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- ONVO Health Care
- LIPO Health Care
- Exchange
- ONVO Nasdaq
- LIPO Nasdaq
- Market Cap
- ONVO 3.0M
- LIPO 3.1M
- IPO Year
- ONVO N/A
- LIPO 2022
- Fundamental
- Price
- ONVO $1.87
- LIPO $2.65
- Analyst Decision
- ONVO
- LIPO
- Analyst Count
- ONVO 0
- LIPO 0
- Target Price
- ONVO N/A
- LIPO N/A
- AVG Volume (30 Days)
- ONVO 347.1K
- LIPO 176.2K
- Earning Date
- ONVO 05-30-2025
- LIPO 05-08-2025
- Dividend Yield
- ONVO N/A
- LIPO N/A
- EPS Growth
- ONVO N/A
- LIPO N/A
- EPS
- ONVO N/A
- LIPO N/A
- Revenue
- ONVO $122,000.00
- LIPO $536,357.00
- Revenue This Year
- ONVO $59.08
- LIPO N/A
- Revenue Next Year
- ONVO $18.24
- LIPO N/A
- P/E Ratio
- ONVO N/A
- LIPO N/A
- Revenue Growth
- ONVO N/A
- LIPO 19.29
- 52 Week Low
- ONVO $1.56
- LIPO $1.97
- 52 Week High
- ONVO $21.96
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- ONVO 37.84
- LIPO 57.23
- Support Level
- ONVO $1.56
- LIPO $2.25
- Resistance Level
- ONVO $1.78
- LIPO $2.44
- Average True Range (ATR)
- ONVO 0.24
- LIPO 0.22
- MACD
- ONVO 0.13
- LIPO 0.04
- Stochastic Oscillator
- ONVO 43.06
- LIPO 88.39
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.